NEW YORK, May 12, 2005 (PRIMEZONE) -- Amersin Life Science Corporation (OTCBB:AMLS) announced today that its subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Co. (Hubei Benda), has applied to the State Food and Drug Administration for a license to produce Yan Hu Ning (Potassium Sodium Dehydroandroan Drographolide Succinate) as a new pharmaceutical in injectable form. It is anticipated that the license will be granted late in the second quarter ending July 31st, 2005.
According to a recent report by the Chinese Southward Medicine Economic Information Center, the global annual incidence of influenza is about 0.6 to 1.2 billion cases. Among those cases, serious influenza represents 3 to 5 million cases resulting in 250,000 to 500,000 deaths. The most prevalent symptom of serious influenza is upper respiratory tract infection. Survival rates are highest among patients receiving immediate medical treatment for serious symptoms.
Yan Hu Ning is prescribed as a fast acting treatment for viral pneumonia and viral infections of the upper respiratory tract and is used extensively throughout China to treat influenza. It is also used to treat chronic bronchitis, gastro-intestinal tract infection and bacillary dysentery.
"The market demand for this new pharmaceutical is 3 billion RMB (US$366 million), said Mr. Charles Wang, President of Hubei Benda, "It is a medicine with enormous domestic market potential. We applied advanced engineering processes to its development and will enjoy a strong competitive position for Yan Hu Ning in the domestic pharmaceuticals market."
About Amersin Life Sciences Corporation:
Amersin's profits are derived from its subsidiary located in Hubei province, the center of pharmaceutical production and research within China and home to very large scale automobile production, abundant natural resources and links to high capacity transportation systems serving the rest of the country. It employs 266 full-time employees and owns two high capacity modern facilities for the production of dosage form pharmaceuticals in injectable form and in solid form including tablets, capsules, granules and oral solutions. Its injection facility is certified to the latest GMP standards and operating profitably. Its solids form facility is scheduled for completion in the second quarter with certification to the latest GMP standards mid third quarter. Following certification it will commercialize additional products from its portfolio of existing licenses, commencing production in the fall, and begin the application process for licenses to produce its two new biotech products used to treat diabetes and certain forms of cancer for release early next year.
Amersin is committed to building investor equity through strategic acquisition and vertical integration of operating subsidiaries and controlling joint venture interests in China to include all facets of pharmaceutical life sciences from raw materials through dosage form production and distribution. It is poised to become one of the leading American corporations to profit from the burgeoning life sciences sector in China. Additional information may be requested via Amersin's web site at http://Amersin.com
"Safe Harbor" Statement:
This news release contains certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the forward-looking statements contained herein. Detailed information about many risk factors are set forth in Amersin's periodic filings with the Securities and Exchange Commission including, but not limited to, those risks and uncertainties listed in the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Management's Discussion and Analysis" in Amersin's most recent Quarterly Report on Form 10-QSB. All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov or the Amersin web site at http://www.amersin.com. Amersin is under no obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.